Meihua Mike Tu

This inventor holds 20 USPTO granted patents and 11 published patent applications, plus 6 CIPO patents and 4 EPO patents, primarily in Glucagon Receptor Modulation. Top assignee: Pfizer Corporation. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Meihua Mike Tu. Retrieved from https://idiyas.com/inventor/meihua-mike-tu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 11)

% Patents Active = 50.0

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 10)

Average Co-Inventor Count = 6.9

ph-index = 3

Forward Citations = 22(Granted Patents)

Location History:

Mystic, CT (US) (2011 - 2014)
Acton, MA (US) (2014 - 2023)

Company Filing History:

20 out of 4,488

Pfizer Corporation

patents

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Glucagon Receptor Modulators

AMPK Activation

Ketohexokinase Inhibitors

Indole Compounds

Indazole Compounds

Glucokinase Activators

Substituted Imidazoles

Propanamide Compounds

Drug Discovery

Type II Diabetes

Quinolinyl Compounds

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637461 - Compounds for the activation of AMPK (2026-05-26),

2. 11634410 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2023-04-25),

3. 10988463 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2021-04-27),

4. 10787438 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2020-09-29),

5. 10174007 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2019-01-08),

6. 9809579 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2017-11-07),

7. 9452999 - Glucagon receptor modulators (2016-09-27),

8. 9394285 - Indole and indazole compounds that activate AMPK (2016-07-19),

9. 9139538 - Quinolinyl glucagon receptor modulators (2015-09-22),

10. 9073871 - Glucagon receptor modulators (2015-07-07),

11. 9056834 - Glucagon receptor modulators (2015-06-16),

12. 8933104 - Glucagon receptor modulators (2015-01-13),

13. 8927577 - Quinolinyl glucagon receptor modulators (2015-01-06),

14. 8889730 - Indole and indazole compounds that activate AMPK (2014-11-18),

15. 8859591 - Glucagon receptor modulators (2014-10-14),

Title: Innovations by Meihua Mike Tu: A Closer Look at His Patent Contributions

Introduction

Meihua Mike Tu, based in Mystic, CT, is a notable inventor whose contributions to the field of pharmaceuticals are reflected in his impressive portfolio of 19 patents. His work primarily centers around innovative compounds that serve significant therapeutic purposes, particularly in the treatment of metabolic disorders.

Latest Patents

One of Meihua Mike Tu's latest patents focuses on "Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors". This patent outlines processes for synthesizing these compounds and details methods for administering them to mammals in need of such treatment. His contributions in this area represent a significant advancement in the development of inhibitors that can potentially impact metabolic health.

Career Highlights

Meihua Mike Tu works at Pfizer Corporation, a global leader in pharmaceuticals known for its innovative research and development in combating various health challenges. His role within the company has allowed him to spearhead critical projects that merge scientific research with practical medicinal applications, ultimately enhancing patient outcomes.

Collaborations

Throughout his career, Mike has collaborated with esteemed colleagues, including Jeffrey Allen Pfefferkorn and Kevin James Filipski. These collaborations have not only enriched his work but have also fostered a dynamic environment for innovation within the research teams.

Conclusion

Meihua Mike Tu’s journey as an inventor demonstrates the profound impact that innovative thinking and collaboration can have on healthcare advancements. With his latest patents addressing critical health challenges, he continues to pave the way for future discoveries in the pharmaceutical industry. His contributions represent a bridge between scientific research and practical applications that can significantly improve therapeutic strategies.

Profile summary based on public USPTO records.